Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 458

1.

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.

Watanabe K, Kuramitsu S, Posey AD Jr, June CH.

Front Immunol. 2018 Oct 26;9:2486. doi: 10.3389/fimmu.2018.02486. eCollection 2018. Review.

2.

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J.

Cytotherapy. 2018 Oct 29. pii: S1465-3249(18)30638-8. doi: 10.1016/j.jcyt.2018.10.003. [Epub ahead of print]

PMID:
30385043
3.

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.

Alcantara M, Tesio M, June CH, Houot R.

Leukemia. 2018 Nov;32(11):2307-2315. doi: 10.1038/s41375-018-0285-8. Epub 2018 Oct 12. Review.

PMID:
30315238
4.

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.

Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Zhang L, Konradt C, Cogdill AP, Panjwani MK, Jiang S, Migliorini D, Dahmane N, Posey AD Jr, June CH, Mason NJ, Lin Z, O'Rourke DM, Johnson LA.

Mol Ther Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002. eCollection 2018 Dec 21.

5.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

PMID:
30275568
6.

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.

Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL.

Clin Cancer Res. 2018 Sep 6. doi: 10.1158/1078-0432.CCR-18-0758. [Epub ahead of print]

PMID:
30190371
7.

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Zhang C, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC.

Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.

PMID:
30030295
8.

Chimeric Antigen Receptor Therapy.

June CH, Sadelain M.

N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169. Review. No abstract available.

PMID:
29972754
9.

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.

Blood. 2018 Sep 6;132(10):1022-1026. doi: 10.1182/blood-2018-03-837609. Epub 2018 Jun 20.

PMID:
29925499
10.

Driving cars to the clinic for solid tumors.

Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD Jr.

Gene Ther. 2018 Jun;25(3):165-175. doi: 10.1038/s41434-018-0007-x. Epub 2018 Jun 7. Review.

PMID:
29880908
11.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ.

Nature. 2018 Jun;558(7709):307-312. doi: 10.1038/s41586-018-0178-z. Epub 2018 May 30.

PMID:
29849141
12.

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH.

Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.

PMID:
29807781
13.

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Ruella M, June CH.

Mol Ther. 2018 Jun 6;26(6):1401-1403. doi: 10.1016/j.ymthe.2018.05.005. Epub 2018 May 19. No abstract available.

PMID:
29784587
14.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ.

Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.

15.

The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.

O'Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, Kam Y, Philipson B, Trefely S, Nunez-Cruz S, Blair IA, June CH, Milone MC.

Sci Rep. 2018 Apr 19;8(1):6289. doi: 10.1038/s41598-018-24676-6.

16.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. [Epub ahead of print]

17.

Immunotherapy for Breast Cancer: Current and Future Strategies.

Williams AD, Payne KK, Posey AD Jr, Hill C, Conejo-Garcia J, June CH, Tchou J.

Curr Surg Rep. 2017 Dec;5. pii: 31. Epub 2017 Oct 10.

18.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
19.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. [Epub ahead of print]

20.

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S.

Cancer Immunol Res. 2018 May;6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314. Epub 2018 Mar 27.

PMID:
29588319
21.

CAR T cell immunotherapy for human cancer.

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC.

Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711. Review.

PMID:
29567707
22.

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.

Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.

PMID:
29567081
23.

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.

Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM.

Neuro Oncol. 2018 Oct 9;20(11):1429-1438. doi: 10.1093/neuonc/noy032.

PMID:
29509936
24.

Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A.

JCI Insight. 2018 Feb 22;3(4). pii: 94952. doi: 10.1172/jci.insight.94952. [Epub ahead of print]

25.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA.

N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

26.

Glycan-directed CAR-T cells.

Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD Jr.

Glycobiology. 2018 Sep 1;28(9):656-669. doi: 10.1093/glycob/cwy008.

PMID:
29370379
27.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH.

JCI Insight. 2018 Jan 11;3(1). pii: 96976. doi: 10.1172/jci.insight.96976. [Epub ahead of print]

28.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.

N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

29.

Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.

Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, Neal LR, Shirai K, Carpenito C, June CH, Zilliox MJ, Paulos CM.

Nat Commun. 2017 Dec 6;8(1):1961. doi: 10.1038/s41467-017-01867-9.

30.

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH.

Mol Ther. 2018 Jan 3;26(1):269-279. doi: 10.1016/j.ymthe.2017.10.012. Epub 2017 Oct 20.

PMID:
29203150
31.

CAR T-Cell Therapies in Glioblastoma: A First Look.

Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD Jr, June CH.

Clin Cancer Res. 2018 Feb 1;24(3):535-540. doi: 10.1158/1078-0432.CCR-17-2871. Epub 2017 Nov 20.

PMID:
29158268
32.

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH.

Cancer Immunol Res. 2017 Dec;5(12):1152-1161. doi: 10.1158/2326-6066.CIR-17-0189. Epub 2017 Nov 6.

PMID:
29109077
33.

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, Wasik MA.

Blood. 2017 Dec 7;130(23):2569-2572. doi: 10.1182/blood-2017-08-802413. Epub 2017 Oct 26. No abstract available.

PMID:
29074500
34.

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Singh N, Shi J, June CH, Ruella M.

Curr Hematol Malig Rep. 2017 Dec;12(6):522-529. doi: 10.1007/s11899-017-0417-7. Review.

PMID:
29039115
35.

Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment.

Abou-El-Enein M, Cathomen T, Ivics Z, June CH, Renner M, Schneider CK, Bauer G.

Cell Stem Cell. 2017 Oct 5;21(4):427-430. doi: 10.1016/j.stem.2017.09.007.

36.

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH.

Mol Ther. 2018 Jan 3;26(1):280-288. doi: 10.1016/j.ymthe.2017.09.008. Epub 2017 Sep 12.

PMID:
28970045
37.

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.

Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, Zhao Y, June CH.

Cell Rep. 2017 Sep 26;20(13):3025-3033. doi: 10.1016/j.celrep.2017.09.002.

38.

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF.

Blood. 2017 Nov 23;130(21):2317-2325. doi: 10.1182/blood-2017-06-786129. Epub 2017 Sep 21.

39.

Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?

June CH, Warshauer JT, Bluestone JA.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004b. No abstract available.

PMID:
28777789
40.

Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.

Kenderian SS, June CH, Gill S.

Methods Mol Biol. 2017;1633:267-276. doi: 10.1007/978-1-4939-7142-8_17.

PMID:
28735493
41.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19;9(399). pii: eaaa0984. doi: 10.1126/scitranslmed.aaa0984.

42.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

43.

Immunotherapy for Brain Tumors.

Sampson JH, Maus MV, June CH.

J Clin Oncol. 2017 Jul 20;35(21):2450-2456. doi: 10.1200/JCO.2017.72.8089. Epub 2017 Jun 22. Review.

PMID:
28640704
44.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.

45.

Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.

Liu X, Jiang S, Fang C, Li H, Zhang X, Zhang F, June CH, Zhao Y.

Protein Cell. 2017 Jul;8(7):514-526. doi: 10.1007/s13238-017-0422-6. Epub 2017 May 18.

46.

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June CH, Warshauer JT, Bluestone JA.

Nat Med. 2017 May 5;23(5):540-547. doi: 10.1038/nm.4321. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

47.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar BR.

Am J Transplant. 2017 Dec;17(12):3098-3113. doi: 10.1111/ajt.14338. Epub 2017 Jun 14.

PMID:
28470889
48.

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA.

J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.

49.

Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA.

Kawalekar O, June CH, Milone MC.

Methods Mol Biol. 2017;1584:443-450. doi: 10.1007/978-1-4939-6881-7_27.

PMID:
28255718
50.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

Supplemental Content

Support Center